Mehdi Lahmar

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 2

Top Topics

Placebo Controlled

Small Cell Lung Cancer

Top Venues

Future oncology (London, England)

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Patrick Schöffski, Mehdi Lahmar, Anthony Lucarelli, Robert G Maki
Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. Future oncology (London, England) (2023)
Patricia M LoRusso, Noboru Yamamoto, Manish R Patel, Scott A Laurie, Todd M Bauer, Junxian Geng, Teffany Davenport, Michael Teufel, Jian Li, Mehdi Lahmar, Mrinal M Gounder
The MDM2-p53 antagonist BI 907828 in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study. Cancer discovery (2023)